Intravenous anti-obsessive agents: a review

Area of Science:

• Neuroscience
• Pharmacology
• Psychiatry

Background:

• Oral antidepressants are first-line OCD treatment but have limitations.
• Low response rates and delayed therapeutic action are common with oral antidepressants.
• Intravenous (i.v.) agents are being explored for faster and potentially greater efficacy.

Purpose of the Study:

• To review existing literature on i.v. antidepressant use for OCD.
• To assess the efficacy and tolerability of i.v. anti-obsessive agents.
• To identify potential benefits for treatment-refractory OCD patients.

Main Methods:

• A Medline search was conducted for studies on i.v. antidepressants for OCD.
• Search terms included various i.v. antidepressants and related terms.
• Relevant articles primarily focused on clomipramine (CMI) and citalopram.

Main Results:

• Intravenous agents were generally well-tolerated, especially in non-responders to oral therapy.
• Initial clinical response may be faster with i.v. administration, but this advantage may diminish over time.
• Preliminary data suggest potential benefits for severe, treatment-refractory OCD with i.v. CMI and citalopram.

Conclusions:

• Intravenous antidepressants show promise for faster onset and potential efficacy in specific OCD populations.
• Further large-scale, controlled trials are necessary to confirm these findings.
• I.v. agents may be a viable option for patients with severe treatment-refractory OCD.